CAR T-Cell Therapy Market Size is Expected to Reach a Value of US$ 11.49 Billion by 2034: Fact.MR Report

The market for CAR T-cell treatment is expected to grow at an astounding 17.7% CAGR from 2024 to 2034, with a projected valuation of US$ 2.25 million in 2024.

Increased leukemia incidence, a surge in research and development to generate novel CAR T-cell therapy, and CAR T-cell therapy's better efficacy over other conventional cancer treatments are the main factors driving the market growth for CAR T-cell therapy.

𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9785

CAR T-cell therapy is a breakthrough approach in the field of cancer treatment. This method of immunotherapy uses the patient's own cells to attack cancer. The remarkable success of CAR T-cell therapy in treating several hematologic malignancies, including certain forms of leukemia and lymphoma, has highlighted the treatment's potential as a game-changing option for patients who have not responded to conventional treatments.

𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 𝐟𝐫𝐨𝐦 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐭𝐮𝐝𝐲

It is projected that the CAR T-cell treatment market will be worth US$ 2.25 billion by 2024.
From 2024 to 2034, the demand for Car T-cell treatment is expected to grow at a CAGR of 17.7%.
The market is expected to reach US$ 11.49 billion by the end of 2034.
In 2024, North America is projected to hold a 65.7% market share.
From 2024 to 2034, the demand for Yescarta (axicabtagene ciloleucel) is anticipated to grow at a CAGR of 17.4%.
Through 2034, the North American market is expected to grow at a CAGR of 16.5%.
The Western European market is expected to grow at a CAGR of 18.7% between 2024 and 2034.

"Chimeric antigen receptor-expressing (CAR) T-cells are engineered from donors or patients to express a specific tumor antigen. Increased research and development in CAR T-cell therapy, along with an increase in cancer incidence, are expected to have an impact on market growth until 2034. A Fact.MR analyst states, "CAR T-cell therapies hold great promise as a novel approach to cancer treatment that harnesses the immune system to combat illness."

𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐝 𝐢𝐧 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭

Autolus Therapeutics
2Seventy Bio, Inc.
Bristol-Myers Squibb
Pfizer
Gilead Sciences
Intellia Therapeutics
Caribou Biosciences, Inc.
Cartesian Therapeutics, Inc.
Novartis AG

𝐑𝐢𝐬𝐢𝐧𝐠 𝐋𝐞𝐮𝐤𝐞𝐦𝐢𝐚 𝐂𝐚𝐬𝐞𝐬 𝐖𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞 𝐅𝐮𝐞𝐥𝐢𝐧𝐠 𝐃𝐞𝐦𝐚𝐧𝐝 𝐟𝐨𝐫 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲

The market for CAR T-cell treatment is being driven in part by the increasing incidence of leukemia. Leukemia is characterized by the uncontrolled proliferation of abnormal white blood cells, and cases of this disease have increased recently.

According to the American Cancer Society, there were roughly 60,650 new cases of leukemia discovered in the US in 2022.
This increase may have multiple causes, such as alterations in lifestyle, environmental exposures, and genetic predispositions. CAR T-cell therapy is one cutting-edge immunotherapy that has grown in favor as a potential leukemia treatment. This therapy approach enhances cancer cell identification and elimination by changing the patient's own T cells.

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=9785

𝐌𝐨𝐫𝐞 𝐕𝐚𝐥𝐮𝐚𝐛𝐥𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐨𝐧 𝐎𝐟𝐟𝐞𝐫

True, With its latest product, MR offers a dispassionate evaluation of the CAR T-cell treatment business covering the years 2018 through 2023 as well as projections for 2024 through 2034.

In six major regions of the world-North America, Latin America, Europe, East Asia, South Asia & Oceania, and MEA-the study provides crucial insights into the market based on product (Yescarta [axicabtagene ciloleucel], Kymriah [tisagenlecleucel], JCAR017 [lisocabtagene maraleucel], bb2121), indication (relapsed large B-cell lymphoma, acute lymphoblastic leukemia [ALL], multiple myeloma), and end user (hospitals, cancer treatment centers).

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.